Glucagonlike peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors in ischemic strokes with diabetes 2

Background and purpose Cardiovascular outcome trials demonstrate that glucagonlike peptide‐1 receptor agonists (GLP‐1RAs) reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes (T2D), whereas dipeptidyl peptidase‐4 inhibitors (DPP‐4is) have not shown cardiovascular b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of neurology 2024-08, Vol.31 (8), p.e16329-n/a
Hauptverfasser:	Hastrup, Sidsel, Hedegaard, Jakob Nebeling, Andersen, Grethe, Rungby, Jørgen, Johnsen, Soren Paaske
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Agonists Cardiovascular diseases cerebrovascular disease/stroke Clinical trials Cohort Studies Comorbidity Denmark - epidemiology Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Female Glucagon-Like Peptide-1 Receptor - agonists Humans Hypoglycemic Agents - therapeutic use Inhibitors Ischemia Ischemic Stroke - drug therapy Ischemic Stroke - epidemiology Male Middle Aged Mortality outcome research Peptidases Peptides Receptors Risk Socioeconomic factors Socioeconomics Stroke
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!